MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Adaptive Biotechnologies Corp

Closed

11.18 -4.03

Overview

Share price change

24h

Current

Min

11.17

Max

11.58

Key metrics

By Trading Economics

Income

3.9M

-30M

Sales

5M

52M

EPS

-0.2

Profit margin

-56.881

Employees

619

EBITDA

-3.3M

-30M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+1.8% upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2025

Market Stats

By TradingEconomics

Market Cap

422M

1.6B

Previous open

15.21

Previous close

11.18

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jul 2025, 23:09 UTC

Earnings

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 Jul 2025, 19:16 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 Jul 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 Jul 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 Jul 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

James Hardie Completes Acquisition of AZEK

1 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Jul 2025, 20:24 UTC

Earnings

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 Jul 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 Jul 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 Jul 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 Jul 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 Jul 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 Jul 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 Jul 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 Jul 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 Jul 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 Jul 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 Jul 2025, 17:01 UTC

Acquisitions, Mergers, Takeovers

Danone Completed Acquisition of Majority Stake in Kate Farms

1 Jul 2025, 16:55 UTC

Earnings

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 Jul 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 Jul 2025, 16:25 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 15:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 Jul 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 Jul 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

1.8% upside

12 Months Forecast

Average 11.86 USD  1.8%

High 15 USD

Low 9 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.